Actuate Therapeutics Inc (ACTU)
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. Its lead candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is being evaluated in a Phase 2 study for metastatic pancreatic ductal adenocarcinoma. The company is also studying elraglusib in a Phase 1/2 trial for refractory pediatric malignancies, including Ewing sarcoma, neuroblastoma, and pediatric leukemias. Founded in 2015 and headquartered in Fort Worth, Texas, the company was previously known as Apotheca Therapeutics, Inc. before adopting its current name in October 2015.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACTU
|
$1.03
|
5.6% Upside
|
Fair
|
$11.68 1,092.2% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
December 2, 2026
|
23.8x
|
23.563 M
|
19.108 M
|
0.0%
|
35.8%
|
-54.0
|
97.0%
|
